FDA approves the first once-monthly subcutaneous olanzapine for schizophrenia
For your practiceNo loading dose, no oral overlap and no post-injection monitoring window: the usual barriers to a long-acting injectable, removed.
AJMC · Oct 9
Where clinicians earn, learn and talk.
Join 652,387 clinicians and growing.
For your practiceNo loading dose, no oral overlap and no post-injection monitoring window: the usual barriers to a long-acting injectable, removed.
AJMC · Oct 9
Remibrutinib becomes the first approved treatment for symptomatic dermographism AJMC · Oct 7
Atezolizumab plus chemotherapy approved for stage III dMMR colon cancer FDA · Oct 8
Tucatinib added to trastuzumab and pertuzumab for HER2-positive maintenance FDA · Oct 7
Pirtobrutinib approved for previously untreated CLL/SLL AJMC · Oct 2
Gabapentin for chronic low back pain linked to higher 10-year dementia risk Reg Anesth Pain Med
Oral icotrokinra holds skin clearance at two years in plaque psoriasis HCPLive · Oct 10
Nemolizumab sustains itch relief for up to three years in AD and prurigo nodularis HCPLive · Oct 10
FDA posts its April–June 2026 potential safety signals from adverse event reports FDA · Sep 30
Kybella labeling updated with warnings on reactions from unapproved use FDA · Sep 15
Boxed warning added to Injectafer for risk of low phosphate FDA · Sep 1
Medicare open enrollment opens Thursday; patients on Part D should re-check formularies CMS · Sep 28
Negotiated Medicare prices for 15 more drugs, including semaglutide, start January 1 Becker’s
Teach what you already know.
Apply to speakNot this oneFree for every verified clinician. Always.
Three panels. One stage.
Paid by Health-Scripts, never a manufacturer. No patient information, ever.
Your peers want to hear from you. Get paid for your time.
Dinner talks, lunch programs and live sessions in your therapy area — with an honorarium for every one you accept.
NPs, PAs, MDs and DOs — from the leaders of America’s biggest institutions to the best-known voice in town. You choose every engagement.
No app, no portal, no schedule to keep. When there’s something worth your time near you, you hear from us — and it’s always yours to pass on.